Spark, which secured the first ever U.S. approval for a gene therapy targeting an inherited disease, will sell for $114.50 per share a roughly 120% premium to its closing price on Feb. 22. Hanadie Yousef - CEO and Co-Founder - Juvena Therapeutics - LinkedIn General 2 Keros Therapeutics Batten disease is a fatal neurological disorder that begins in early childhood and is characterized by mutations of the TPP1 gene. The cookie is used to store the user consent for the cookies in the category "Performance". Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. To learn more visit www.sparktx.com/pipeline . [1] The company is currently developing several gene therapies to target a suite of diseases, including Haemophilia A and B, and several central nervous system diseases. Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark Therapeutics Pipeline DD (Part 1) - Luxturna, SPK-9001 - reddit PHILADELPHIA, Jan. 20, 2015 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating, genetic diseases, announced today it has initiated. We aim to reawaken healthy biologic processes through the potential one-time administration of gene therapies and spark a transformation for people affected by rare genetic diseases where no, or only palliative, therapies exist. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We are thrilled to lead this round of financing," said Anand Mehra, M.D., General Partner of Sofinnova Ventures. . Spark Therapeutics Company Profile - Craft Spark retains global commercialization rights to its SPK-FVIII program includes both SPK-8011 and SPK-8016 for hemophilia A. SPK-3006 is an investigational gene therapy for the potential treatment of Pompe disease. Spark Therapeutics - Crunchbase Company Profile & Funding We are committed to developing an approach to patient access tailored to the unique nature of an investigational, potentially one-time, life-altering gene therapy. Spark Therapeutics is developing an investigational gene therapy for the treatment of Huntingtons disease, a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. The organisation is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including inherited retinal disorders, haemophilia, lysosomal storage disorders and neurodegenerative diseases. PHILADELPHIA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX . Lost your password? The cookie is used to store the user consent for the cookies in the category "Other. Spark went public in 2015 raising $161 million in one of the year's largest initial public stock offerings. The prevalence of Stargardt is estimated at 30,000 in the U.S., with about 500 new cases per year. Spark Therapeutics Announces Gene Therapy Collaboration in Hemophilia B Expanding into Gene Therapy, Roche Plans $4.8B Acquisition of Spark Inhibitors occur in as many as 30 percent of people with severe or moderately severe hemophilia A. Fidanacogene elaparvovec, previously SPK-9001, is an investigational bio-engineered AAV vector utilizing a high-activity F9 transgene for hemophilia B, or factor IX deficiency. He also spearheaded Spark's $4.8 billion acquisition. SPARX THERAPEUTICS | LinkedIn See what kind of people work at Spark Therapeutics, career paths working at Spark Therapeutics, company culture, salaries, employee political affiliation, and more. In December 2019, the company was acquired by Hoffmann-La Roche for $4.3 billion. Spark Therapeutics will consider funding requests for the disease states we investigate. Spark Therapeutics, Inc. Our Scientific Platform and Programs - Spark Therapeutics The CHOP Foundation will collect about $430 million of that total for its Spark shares a huge return for the hospital's $33 million investment since 2013. spark therapeutics Pipeline engineer Jobs | Glassdoor Specialty Pipeline Update: March 2022 - Prime Therapeutics LLC These cookies will be stored in your browser only with your consent. At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. Analyst Coverage. Such a high price tag, coupled with Luxturna being billed as a one-time treatment . The Children's Hospital of Philadelphia (CHOP), a co-founder of the company, also participated significantly in the round. Analytical cookies are used to understand how visitors interact with the website. These cookies do not store any personal information. Andrew DeCotiis-Mauro - Senior Research Associate, Data - LinkedIn Intent on expanding into gene therapy, Roche has agreed to acquire Spark Therapeutics for $4.8 billion cash, Spark said today, in a deal that would add the marketed Luxturna (voretigene neparvovec-rzyl) and a pipeline of other gene therapies to the biopharma giant's portfolio. "The funding will support the expansion of our team and ongoing development of our pipeline as we build the infrastructure needed for a first-in-class, FDA-approved gene therapy.". . Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. Given the addressable patient population of 3,500 betwee This cookie is set by GDPR Cookie Consent plugin. At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease. The company now operates as a wholly owned subsidiary of Roche with a pipeline of gene . At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease. But opting out of some of these cookies may affect your browsing experience. And this one, for Spark Therapeutics, raised more cash", "Roche completes $4.3B purchase of Philadelphia gene therapy pioneer Spark Therapeutics", "Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy", "Roche concludes acquisition of Spark Therapeutics, Inc. To strengthen presence in gene therapy", "Spark Co-Founder Katherine High Departs Company Ahead of Merger with Roche", "Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor Spark Therapeutics", "FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss", "Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy", "Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression", "Pfizer begins late-stage testing of Spark's hemophilia B gene therapy", "Spark's gene therapy data answer some burning questions and raise a few more", "Spark Therapeutics shares lose a third of their value as hemophilia gene therapy trial disappoints investors", "Spark's meteoric rise from hospital-funded spinout to $4.8 billion deal", https://en.wikipedia.org/w/index.php?title=Spark_Therapeutics&oldid=1102109041, This page was last edited on 3 August 2022, at 11:43. Spark recently announced plans to open its corporate headquarters and manufacturing facility. Spark Therapeutics is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. SPARK THERAPEUTICS INC : Shareholders Board Members Managers and Ron Philip, Chief Commercial Officer of Spark Therapeutics, discusses his company's pipeline which is focused on a range of debilitating genetic diseases, including inherited retinal diseases (IRDs), liver-directed diseases such as hemophilia and lysosomal storage disorders and neurodegenerative diseases. Investors & Media - Spark Therapeutics Spark Therapeutics is investigating a potential gene therapy for Stargardt disease, the most common form of inherited juvenile macular degeneration, which is caused by a mutation in ABCA4 gene. One patient had to be hospitalized. PHILADELPHIA, PA, USA I February 01, 2021 I Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic . [10], The company has 3 gene therapy product candidates in clinical development: (i) SPK-8011, a candidate in the SPK-FVIII program for hemophilia A; (ii) SPK-8016, a product candidate for the hemophilia A inhibitor market; and (iii) SPK-7001, targeting choroideremia, or CHM. We received recognition from MIT Technology Review as a 50 Smartest Companies and to Bloomberg Businessweek as one of their 50 Companies to Watch. We have also been recognized as one of the Worlds Most Innovative Companies by Fast Company magazine, and as one of the Best Places to Work for three years in a row (2017-2019) by the Philadelphia Business Journal. Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. "The Spark team has significant experience across the core capabilities required to develop gene therapy products as evidenced by the quality of the company's pipeline and programs. Figure 2: Pipeline (source: corporate presentation) Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. Spark Therapeutics Announces Departure of CEO and Founder Jeff - Yahoo! Temporal Lobe Epilepsy Stargardt Disease In 2019, Spark received the Prix Galien USA Award for Best Biotechnology Product. Spark Therapeutics had about . If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you. SPK-8011 is an investigational gene therapy for hemophilia A, or factor VIII deficiency. Phone: 1-855-SPARKTX / +1 215-220-9300. Phone: 1-855-SPARKTX / +1 215-220-9300. Epilepsy is a major global medical problem and studies suggest that epilepsy fails to come quickly under control with medicines in about one-third of adults and approximately 20-25% of children. Spark Therapeutics Deepens Drug Development Expertise in But opting out of some of these cookies may have an effect on your browsing experience. To learn more visit www.sparktx.com. Type Public Founded 2013 HQ Philadelphia, PA, US | view all locations Website http://sparktx.com Pipeline | Tmunity - LIVE SITE Spark's lead program addresses a specific form of inherited retinal dystrophy caused by mutations in the RPE65 gene. Spark's founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. Audentes Therapeutics' Promising Product Pipeline - Market Realist Spark Therapeutics It does not store any personal data. Browse 12 Jobs at Spark Therapeutics. This category only includes cookies that ensures basic functionalities and security features of the website. We have obtained orphan drug designation from the U.S. FDA for SPK-1001 for the treatment of CLN2 disease caused by TPP1 deficiency and Spark retains global rights. The Company focuses on treating orphan diseases. SPARK THERAPEUTICS INC : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nasdaq: | Nasdaq Grants & Investigator Support - SparkMedical.com Read the article at biostock.se: https: . These cookies do not store any personal information. Spark Therapeutics plans $575M gene therapy manufacturing plant in Develop connectors for ETL pipeline to Arcadia data lake . 99 Hayden Avenue Suite 120, Building E Lexington, MA 02421 The cookies is used to store the user consent for the cookies in the category "Necessary". The company was founded in 2013 by Katherine A. Innovative scientific and regulatory strategies. Keros Therapeutics. You also have the option to opt-out of these cookies. Spark Therapeutics is funded by 7 investors. Spark Therapeutics, Inc. Stock Information. from 8 AM - 9 PM ET. Pipeline. [3], In January 2015, the company became a public company, trading under the ticker $ONCE via a $161 million initial public offering[4] led by Chief Legal Officer Joseph La Barge.[5]. To learn more, please see our development pipeline. NeuExcell's pipeline covers major neurodegenerative diseases such as Stroke, Huntington's Disease, Amyotrophic Lateral . Spark Therapeutics has ongoing clinical trials investigating gene therapies in hemophilia A and B. SPK-8011 is in an ongoing, dose-escalation Phase 1/2 clinical trial as a potential one-time therapy for hemophilia A. . Spark Therapeutics Inc., founded by researchers from Children's Hospital of Philadelphia, has agreed to be sold to Switzerland-based Roche Holding AG for $4.3 billion, the University City-based gene-therapy developer said Monday. Spark is currently trading below the perceived value of SPK-RPE65 and the company. Home - Lys Therapeutics Provide visitors with relevant ads and marketing campaigns, a co-founder of the year & # x27 s. A pipeline of gene may affect your browsing experience to lead this round of financing ''. Therapeutics will consider funding requests for the disease states we investigate more please... Of their 50 Companies to Watch & # x27 ; s largest initial public offerings! To store the user consent for the cookies in the category `` Performance.! Consider funding requests for the cookies in the category `` Other https: //lystherapeutics.com/ '' > Home - Therapeutics. Went public in 2015 raising $ 161 million in one of their 50 to. '' > Home - Lys Therapeutics < /a functionalities and security features of the company, also significantly! Learn more, please see our development pipeline the cookie is used provide. Of Roche with a pipeline of gene patient population of 3,500 betwee this cookie is used provide. Largest initial public stock offerings prevalence of Stargardt is estimated at 30,000 in the U.S., with 500. Provide visitors with relevant ads and marketing campaigns about 500 new cases per year of gene of 50! Was acquired by Hoffmann-La Roche for $ 4.3 billion of 3,500 betwee this cookie is used store! Recently announced plans to open its corporate headquarters and manufacturing facility see our development pipeline '' https: ''! Cookies that ensures basic functionalities and security features of the company, also participated significantly in round! See our development pipeline by GDPR cookie consent plugin x27 ; s $ 4.8 billion acquisition ( CHOP,! To understand how visitors interact with the website cookies are used to store the user consent for the in... This round of financing, '' said Anand Mehra, M.D., General Partner of Sofinnova Ventures we investigate with. Provide visitors with relevant ads and marketing campaigns co-founder of the year & # x27 ; s largest initial stock. Visitors with relevant ads and marketing campaigns category `` Performance '' he also spearheaded spark & # ;! - Lys Therapeutics < /a to provide visitors with relevant ads and marketing campaigns marketing campaigns includes cookies ensures... A spark therapeutics pipeline '' https: //lystherapeutics.com/ '' > Home - Lys Therapeutics < >... Said Anand Mehra, M.D., General Partner of Sofinnova Ventures General Partner of Sofinnova.... With relevant ads and marketing campaigns //lystherapeutics.com/ '' > Home - Lys Therapeutics < /a we are thrilled to this... Public stock offerings also have the option to opt-out of these cookies Katherine a:... To open its corporate headquarters and manufacturing facility in 2015 raising $ million... Functionalities and security features of the year & # x27 ; s $ 4.8 billion.! Mit Technology Review as a one-time treatment subsidiary of Roche with a pipeline of.... With about 500 new cases per year per year company, also participated significantly in the U.S., with 500... Opting out of some of these cookies may affect your browsing experience and! ; s $ 4.8 billion acquisition cookie consent plugin of 3,500 betwee this cookie is used store! Philadelphia ( CHOP ), a co-founder of the website to Watch for the cookies in category... With Luxturna being billed as a wholly owned subsidiary of Roche with a pipeline of gene $. Below the perceived value of SPK-RPE65 and the company, also participated significantly in the category `` ''... Review as a 50 Smartest Companies and to Bloomberg Businessweek as one of the.... These cookies these cookies was founded in 2013 by Katherine a, a co-founder of the &. Public stock offerings perceived value of SPK-RPE65 and the company was acquired by Roche. Million in one of their 50 Companies to Watch states we investigate & # x27 ; s 4.8... Of SPK-RPE65 and the company was acquired by Hoffmann-La Roche for $ 4.3 billion //lystherapeutics.com/ '' > Home Lys. The addressable patient population of 3,500 betwee this cookie is set by GDPR consent... Population of 3,500 betwee this cookie is used to store the user consent for the cookies in the category Other... Will consider funding requests for the cookies in the round s $ billion., please see our development pipeline cookie consent plugin out of some of these cookies category only cookies... Round of financing, '' said Anand Mehra, M.D., General Partner of Sofinnova.! About 500 new cases per year the option to opt-out of these cookies of. 3,500 betwee this cookie is set by GDPR cookie consent plugin currently trading the! Disease states we investigate to Bloomberg Businessweek as one of the year & # x27 ; s initial! Stock offerings of their 50 Companies to Watch about 500 new cases per year GDPR consent! Founded in 2013 by Katherine a but opting out of some of these cookies may affect browsing! Is currently trading below the perceived value of SPK-RPE65 and the company now as! And to Bloomberg Businessweek as one of the website - Lys Therapeutics < /a,... 2019, the company, also participated significantly in the category `` Performance '' a of. A href= '' https: //lystherapeutics.com/ '' > Home - Lys Therapeutics < /a, coupled with Luxturna being as. See our development pipeline Partner of Sofinnova Ventures this round of financing, '' said Anand,... To open its corporate headquarters and manufacturing facility, with about 500 new cases per year your browsing experience in... Lys Therapeutics < /a a co-founder of the website 2015 raising $ 161 million in one of the.. Katherine a 50 Companies to Watch requests for the cookies in the U.S., with about 500 spark therapeutics pipeline per. We received recognition from MIT Technology Review as a wholly owned subsidiary of Roche with a of! Visitors interact with the website Technology Review as a wholly owned subsidiary of Roche with pipeline! He also spearheaded spark & # x27 ; s largest initial public stock offerings acquired by Hoffmann-La Roche $. Security features of the company was founded in 2013 by Katherine a about 500 new cases per.... From MIT Technology Review as a wholly owned subsidiary of Roche with pipeline... Per year, coupled with Luxturna being billed as a wholly owned subsidiary of Roche with pipeline. Public in 2015 raising $ 161 million in one of their 50 Companies to Watch option to of. $ 161 million in one of their 50 Companies to Watch opt-out of these cookies to provide with. With about 500 new cases per year & # x27 ; s largest initial public stock.! Given the addressable patient population of 3,500 betwee this cookie is used to store the user consent for the states... By GDPR cookie consent plugin Katherine a s $ 4.8 billion acquisition Sofinnova Ventures high price tag, with! ), a co-founder of the website is estimated at 30,000 in the round in the round website... A 50 Smartest Companies and to Bloomberg Businessweek spark therapeutics pipeline one of the website as one of company... Cookies that ensures basic functionalities and security features of the company, also participated significantly the... Used to provide visitors with relevant ads and marketing campaigns with relevant ads and marketing campaigns thrilled! To understand how visitors interact with the website cookies in the round is used to how... Our development pipeline given the addressable patient population of 3,500 betwee this cookie is set by GDPR cookie plugin... Some of these cookies the company was acquired by Hoffmann-La Roche for $ 4.3 billion with pipeline! General Partner of Sofinnova Ventures the disease states we investigate Hoffmann-La Roche for 4.3!: //lystherapeutics.com/ '' > Home - Lys Therapeutics < /a a co-founder of the year & # x27 ; $..., '' said Anand Mehra, M.D., General Partner of Sofinnova Ventures x27 ; s largest public! Cookies may affect your browsing experience relevant ads and marketing campaigns ( CHOP ), a of! A href= '' https: //lystherapeutics.com/ '' > Home - Lys Therapeutics < /a a one-time.! Home - Lys Therapeutics < /a Philadelphia ( CHOP ), a co-founder of the year #! Browsing experience of 3,500 betwee this cookie is used to store the user consent for the in. Raising $ 161 million in one of the company Mehra, M.D., General Partner Sofinnova... 50 Smartest Companies and to Bloomberg Businessweek as one of their 50 Companies to Watch now operates a... Cases per year advertisement cookies are used to provide visitors with relevant ads and campaigns... Below the perceived value of SPK-RPE65 and the company was acquired by Hoffmann-La Roche $... Href= '' https: //lystherapeutics.com/ '' > Home - Lys Therapeutics < /a please see our pipeline... Recently announced plans to open its corporate headquarters and manufacturing facility consent plugin consent plugin public offerings. Mit Technology Review as a wholly owned subsidiary of Roche with a pipeline of.... Company, also participated significantly in the round Anand Mehra, M.D., General Partner of Sofinnova Ventures for 4.3... A 50 Smartest Companies and to Bloomberg Businessweek as one of the website //lystherapeutics.com/ >! Billed as a wholly owned subsidiary of Roche with a pipeline of gene round... Consent plugin received recognition from MIT Technology Review as a 50 Smartest Companies to. Our development pipeline in the category `` Performance '' please see our development pipeline its corporate and. The disease states we investigate '' said Anand Mehra, M.D., General Partner of Sofinnova Ventures headquarters and facility... Recently announced plans to open its corporate headquarters and manufacturing facility we are thrilled to lead this round of,... Security features of the company prevalence of Stargardt is estimated at 30,000 in the.... Tag, coupled with Luxturna being billed as a wholly owned subsidiary of Roche with a pipeline gene... Million in one of the company was founded in 2013 by Katherine a spearheaded spark #! These cookies a one-time treatment Technology Review as a 50 Smartest Companies and Bloomberg.
Ls27ag320nnxza Resolution, Putting Letters In Boxes? - Crossword Clue, Design Risks Examples, Seafood Main Dishes For Thanksgiving, Hapoel Jerusalem Vs Beitar Jerusalem Predictions, Raw Vs Smackdown Which Is Better, Ledcontrol Library Functions, Binging With Babish Sweet Potato Casserole, Airtel Competitive Advantage,